Adaptimmune Therapeutics Faces Delisting Concerns
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Adaptimmune might get delisted - big trouble for the stock.
AI Summary
Adaptimmune Therapeutics PLC filed an 8-K on October 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing also includes Regulation FD disclosures and financial statements and exhibits. The report date for the earliest event is October 15, 2025.
Why It Matters
This filing indicates potential issues with Adaptimmune Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's public trading status and investor confidence.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- October 15, 2025 (date) — Earliest event reported
- October 20, 2025 (date) — Filing date
FAQ
What specific listing rule or standard has Adaptimmune Therapeutics PLC failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice has been issued regarding potential delisting or failure to satisfy a continued listing rule or standard.
What is the significance of the 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'?
This notice indicates that the company may be at risk of having its securities delisted from the stock exchange, which could negatively impact its liquidity and market value.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 15, 2025.
What other items are included in this 8-K filing besides the delisting notice?
This 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
What is the primary business of Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC is involved in Biological Products (excluding diagnostic substances), as indicated by its Standard Industrial Classification code.
Filing Stats: 1,148 words · 5 min read · ~4 pages · Grade level 14.9 · Accepted 2025-10-20 07:50:19
Filing Documents
- adap-20251015x8k.htm (8-K) — 40KB
- adap-20251015xex99d1.htm (EX-99.1) — 12KB
- adap-20251015xex99d1001.jpg (GRAPHIC) — 11KB
- adap-20251015xex99d1002.jpg (GRAPHIC) — 4KB
- 0001104659-25-100618.txt ( ) — 189KB
- adap-20251015.xsd (EX-101.SCH) — 3KB
- adap-20251015_lab.xml (EX-101.LAB) — 16KB
- adap-20251015_pre.xml (EX-101.PRE) — 11KB
- adap-20251015x8k_htm.xml (XML) — 5KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 16, 2025, Adaptimmune Therapeutics plc (the "Company") notified The Nasdaq Stock Market, LLC , pursuant to authorization by its Board of Directors on October 15, 2025, that it intends to file a Form 25 with the U.S. Securities and Exchange Commission (the "SEC") on or about October 28, 2025 to effect the voluntary delisting of the Company's American Depositary Shares ("ADSs") from The Nasdaq Capital Market ("Nasdaq") and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Following confirmation by The Nasdaq Stock Market, LLC on October 17, 2025, the Company currently expects that the trading of its ADSs on Nasdaq will be suspended following the closing of trading on Nasdaq on or about October 27, 2025. Ninety days after the date of filing of the Form 25, the deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to become effective. Following the delisting of the Company's ADSs from Nasdaq, the Company intends to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record, upon which the Company's filing obligations under the Exchange Act will immediately be suspended, including the obligations to file all periodic reports. Following the delisting, any trading in the Company's ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company currently expects that its ADSs will be quoted on the OTC Pink Limited Market, a market operated by OTC Markets Group Inc. (an "OTC market"), so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 20, 2025, the Company issued a press release relating to the Company's voluntary delisting of its ADSs from Nasdaq. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," or the negative of these terms, or other comparable terminology. These statements are based on our current expectations, estimates, and projections about our business and industry, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, risks associated with, and the timing and effectiveness of, the Company's voluntary delisting from Nasdaq; the Company's plans with respect to the delisting and deregistration of its ADSs; uncertainties regarding eligibility for and timing of quotation on an OTC market; and the trading of the Company's ADSs following the voluntary delisting of the ADSs from Nasdaq. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to the risks described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this current report on Form 8-K speak only as of the date the
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press release dated October 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date:October 20, 2025 By: /s/ Adrian Rawcliffe Name: Adrian Rawcliffe Title: Chief Executive Officer